<SEC-DOCUMENT>0001564590-15-005473.txt : 20150716
<SEC-HEADER>0001564590-15-005473.hdr.sgml : 20150716
<ACCEPTANCE-DATETIME>20150716171742
ACCESSION NUMBER:		0001564590-15-005473
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20150716
DATE AS OF CHANGE:		20150716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		15992084

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>abio-424b4live.htm
<DESCRIPTION>424B4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20150715.htm
</title>
</head>
<!-- NG Converter v4.0.1.0 -->
<body>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;">Prospectus Supplement No. 40</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(to Prospectus dated May 30, 2013)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed pursuant to Rule 424(b)(4) <br>Registration No. 333-187508 </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">125,000 Shares of Series A Convertible Preferred Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12,500,000 Shares of Common Stock Underlying the Preferred Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants to Purchase up to 6,250,000 Shares of Common Stock and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6,250,000 Shares of Common Stock Underlying the Warrants </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201507162049381403349.jpg" title="" alt="" style="width:172px;height:58px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;This prospectus supplement supplements the prospectus dated May 30, 2013 (the &#8220;Prospectus&#8221;),<font style="font-family:Calibri;"> </font>as supplemented by that certain Prospectus Supplement No.&#160;1 dated July&#160;17, 2013 (&#8220;Supplement No.&#160;1&#8221;), by that certain Prospectus Supplement No.&#160;2 dated July&#160;19, 2013 (&#8220;Supplement No.&#160;2&#8221;), by that certain Prospectus Supplement No.&#160;3 dated July&#160;24, 2013 (&#8220;Supplement No.&#160;3&#8221;), by that certain Prospectus Supplement No.&#160;4 dated July&#160;30, 2013 (&#8220;Supplement No.&#160;4&#8221;), by that certain Prospectus Supplement No. 5 dated August 6, 2013 (&#8220;Supplement No. 5&#8221;), by that certain Prospectus Supplement No. 6 dated September 4, 2013 (&#8220;Supplement No. 6&#8221;), by that certain Prospectus Supplement No. 7 dated September 23, 2013 (&#8220;Supplement No. 7&#8221;), by that certain Prospectus Supplement No. 8 dated October 29, 2013 (&#8220;Supplement No. 8&#8221;), by that certain Prospectus Supplement No. 9 dated November 6, 2013 (&#8220;Supplement No. 9&#8221;), by that certain Prospectus Supplement No. 10 dated November 13, 2013 (&#8220;Supplement No. 10&#8221;), by that certain Prospectus Supplement No. 11 dated November 21, 2013 (&#8220;Supplement No. 11&#8221;), by that certain Prospectus Supplement No. 12 dated December 5, 2013 (&#8220;Supplement No. 12&#8221;), by that certain Prospectus Supplement No. 13 dated January 8, 2014 (&#8220;Supplement No. 13&#8221;), by that certain Prospectus Supplement No. 14 dated February 10, 2014 (&#8220;Supplement No. 14&#8221;), by that certain Prospectus Supplement No. 15 dated February 12, 2014 (&#8220;Supplement No. 15&#8221;), by that certain Prospectus Supplement No. 16 dated February 18, 2014 (&#8220;Supplement No. 16&#8221;), by that certain Prospectus Supplement No. 17 dated March 3, 2014 (&#8220;Supplement No. 17&#8221;), by that certain Prospectus Supplement No. 18 dated March 20, 2014 (&#8220;Supplement No. 18&#8221;), by that certain Prospectus Supplement No. 19 dated May 13, 2014 (&#8220;Supplement No. 19&#8221;), by that certain Prospectus Supplement No. 20 dated June 9, 2014 (&#8220;Supplement No. 20&#8221;), by that certain Prospectus Supplement No. 21 dated August 13, 2014 (&#8220;Supplement No. 21&#8221;), by that certain Prospectus Supplement No. 22 dated August 18, 2014 (&#8220;Supplement No. 22&#8221;), by that certain Prospectus Supplement No. 23 dated November 12, 2014 (&#8220;Supplement No. 23&#8221;), by that certain Prospectus Supplement No. 24 dated December 1, 2014 (&#8220;Supplement No. 24&#8221;), by that certain Prospectus Supplement No. 25 dated December 10, 2014 (&#8220;Supplement No. 25&#8221;), by that certain Prospectus Supplement No. 26 dated December 11, 2014 (&#8220;Supplement No. 26&#8221;), by that certain Prospectus Supplement No. 27 dated December 30, 2014 (&#8220;Supplement No. 27&#8221;), by that certain Prospectus Supplement No. 28 dated February 4, 2015 (&#8220;Supplement No. 28&#8221;), by that certain Prospectus Supplement No. 29 dated February 17, 2015 (&#8220;Supplement No. 29&#8221;), by that certain Prospectus Supplement No. 30 dated February 23, 2015 (&#8220;Supplement No. 30&#8221;), by that certain Prospectus Supplement No. 31 dated March 16, 2015 (&#8220;Supplement No. 31&#8221;), by that certain Prospectus Supplement No. 32 dated March 19, 2015 (&#8220;Supplement No. 32&#8221;), by that certain Prospectus Supplement No. 33 dated April 13, 2015 (&#8220;Supplement No. 33&#8221;), by that certain Prospectus Supplement No. 34 dated April 14, 2015 (&#8220;Supplement No. 34&#8221;), by that certain Prospectus Supplement No. 35 dated May 12, 2015 (&#8220;Supplement No. 35&#8221;), by that certain Prospectus Supplement No. 36 dated June 5, 2015 (&#8220;Supplement No. 36&#8221;), by that certain Prospectus Supplement No. 37 dated June 11, 2015 (&#8220;Supplement No. 37&#8221;), and by that certain Prospectus Supplement No. 38 dated June 11, 2015 (&#8220;Supplement No. 38), and by that certain Prospectus Supplement No. 39 dated June 23, 2015 (&#8220;Supplement No. 39&#8221;, and together with Supplement No. 1, Supplement No. 2, Supplement No. 3, Supplement No. 4, Supplement No. 5, Supplement No. 6, Supplement No. 7, Supplement No. 8, Supplement No. 9, Supplement No. 10, Supplement No. 11, Supplement No. 12, Supplement No. 13, Supplement No. 14, Supplement No. 15, Supplement No. 16, Supplement No. 17, Supplement No. 18, Supplement No. 19, Supplement No. 20, Supplement No. 21, Supplement No. 22, Supplement No. 23, Supplement No. 24, Supplement No. 25, Supplement No. 26, Supplement No. 27, Supplement No. 28, Supplement No. 29, Supplement No. 30, Supplement No. 31, Supplement No. 32, Supplement No. 33, Supplement No. 34, Supplement No. 35, Supplement No. 36, Supplement No. 37, and Supplement No. 38, the &#8220;Supplements&#8221;), which form a part of our Registration Statement on Form S-1 (Registration No.&#160;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on July 16, 2015 (the &#8220;Current Report&#8221;).&nbsp;&nbsp;Accordingly, we have attached the Current Report to this prospectus supplement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible Preferred Stock (&#8220;Preferred Stock&#8221;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants.</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and supplements the information in the Prospectus and the Supplements.  If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus supplement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;Our common stock is traded on the Nasdaq Global Market under the trading symbol &#8220;ABIO.&#8221; On July 16, 2015, the last reported sale price of our common stock was $1.21 per share. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page 5 of the Prospectus and beginning on page 22 of our quarterly report on Form 10-Q for the period ended March 31, 2015 before you decide whether to invest in shares of our common stock.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus supplement is July 16, 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>

<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): July 16, 2015 (July 15, 2015)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO 80020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices) (Zip Code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(720) 940-2200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><a name="OLE_LINK9"></a><a name="OLE_LINK10"></a><font style="font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3 &#8212; Securities and Trading Markets</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.01.&nbsp;&nbsp;Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 15, 2015, The Nasdaq Stock Market, notified ARCA biopharma, Inc. (&#8220;ARCA&#8221; or the &#8220;Company&#8221;) that the Company had regained compliance with the applicable minimum bid price rule of The NASDAQ Capital Market <font style="color:#;">as set forth in NASDAQ Rule 5550(a)(2). Accordingly, the previous notice received by the Company on February 18, 2015 is now closed.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 22, 2015, the Company&#8217;s stockholders <font style="color:#;">authorized the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) for a period of up to one year, to effect a reverse split of the Company&#8217;s Common Stock, as described in more detail in the Company&#8217;s 2015 Proxy Statement.&nbsp;&nbsp;Although the Company has regained compliance with the Nasdaq listing standards, the Company&#8217;s Board may still elect to proceed with the reverse split if, in the Board&#8217;s judgment, it is considered to be in the best interest of the Company&#8217;s </font>stockholders.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: July 16, 2015</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g201507162049381403349.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201507162049381403349.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``[`*T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U/6?$-Q]I
M>TL7V!#M:4#))]JS8[S5)>1?3^O#U7@B,L[DMR7/4^];]M:+&GG2@1E.6./E
M8?XU\?&>(QE5R<FD>FU"E&R1FF;5`BG[;<\GKNJ%[[5(7.;VX./]K-=''%;R
M(FQ7V(Q*DCK]:H7M@54[4R?XI3T_"M:N%K1ASPFW\V1&K%NS1:T+79+V0VMU
MQ,!E6`QN_P#KUT(.:X32$V:];X(.2<_E7="O7RFO4K4/WCNT['/B81A/W1:Y
MSQ'XMM?#M[I=M.-QO9MC'./+7IO/KR0*Z+(!YKQ7QE;3>)-.U+Q5&6^SVER+
M6W'_`$Q4X9_Q<Y_"O4.<]J!R*;*66-BBEF`)"@XR?2L#P3K/]N>$[&[9LS*G
ME3'_`&UX/Y\'\:Z*@#AM3^(QT*2./5_#NHVC2`E#OC=6QUP0:M6GC+4=1M$O
M++PEJ<MLZ[E=I(D+#U`+<USWQG`&E:5[W#_^@&NW\*\^$='X_P"7.+_T$4`9
M^B^.]*U?4&TQQ/8ZDI*FUO$V-D=@>A-=0",5XE\1XV;XD6B6"DWC)"0$Z^9N
MX_'%>LZ_JZ:%H-WJ4HW""/(7^\W0#\Z`(=?\5Z3X;B5M1N=LK_ZN",;I'^BB
MLR'Q%XFU"+SK#PJ8H6Y5K^[6)B/]T`D?C7(_#?29/$.L7OBC5R;B>.3;$7Y&
M_')`]`,`"O6@.*`.#U3X@ZGX>*'7/"US!&W2:"X61"?3.!S[&NWL[E;RTAN4
M^Y+&LB@]@1FH=5TVVU?3;C3[N,/#.A1@?Y_6FZ19/INDVEE)+YKV\2QE\8W8
M[T`7CTZXKG;OQ9;6GC*R\.LO[VXA,AD+8"-_"N.Y.#6Y=7,5I:37,S;8HD+N
M?0`9KPSQ):Z@++3O&SEEN+ZZ,@7_`)Y*#F$?]\C]:`/>ATHJCI6I1ZMI=I?P
M',=Q$)![9ZC\\U>H`\_LROG-E"?F/0^];-^K_P!F+L3&QP[('+$#UQVYKG@S
M6]U)&V58.01Z<UM6.H+&55#M0<N>[8[5\;A*D4I4IZ7T/3JQ>DD3VNJHL.P$
M'<,8JQ=9:VC\Q"S*/F&_&W\*A6[MTV2B*%7=F#,JX(^E9][>B08<@N.`_J/>
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M<C^RM)[C[0__`*`:2>?Q?HW@*QU+3;^VFMDM8V:+[+\\2;1@@Y^;'>H?C+>V
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M&J37'A8:QK%VJ_:I'G'F.`L4>?E4>P`H`I?$.[N+BUL_#UBC376IR@/&C;3Y
M*\OR>F<8S5?Q)'J^N>%[C2O^$5F@0(/*;[5&?+*_=.!].E0^$=0M?$WCK5]=
M\]&6W1;6S0MSL[MCW->@LX49)Q[F@#SCX0ZR;G2KK2)3\]J_F1`]=C=1^#9_
M.O2Z\,>_M?!7Q7GDCG3["TG[T*V=L<@R1^!YKVJWOK6Y@2>"YAEB<95U<$$>
MU`&=JN@1:A)YR.89NY`R&^HK+7PM>J"!=1<^QKKJ*X*V68:K/GE'7RT-HUZD
M59,Y3_A&K[:!]IBX]C3#X5O&;+7,6._RFNNHQ67]CX7L_O97UFIW,S2M'@TM
M&V,9)7^\[#D_3T%3ZAIEEJEN+>^MUGBW;MCYQD5<IDK+&C.YPJ@DGVKT*=*%
M**A!62,)2<G=F(WA/PU)B+^R++*C("H`0/PYK9$$:PB':!$%V;?;&,5SNBWM
MO%*TKHXDOICM95RJC^%<^O?%:FJWEK%:M#<^8RRX0K%][!.*T$5H_!_AV/.-
M&LR3W9-Q_,U-:^&=%L;EKBTTVW@E92C-&NW(/4<5:>6WTNR0.Y6-`$3/+,>P
M'J:=:WJ732H`\<L1`>-Q@C(R*`,V+P?X<B/R:-9Y/=HPQ_6IK7PSHEA>K>6F
MF6\%PN</&NWJ.>E17.N>1J+QQQF2V@C+W#HN2ASQ_4UIM=1"R:Z+`P^7YF[M
MMQF@""^TW3M7A$%];0W21ON"2`-M;UJ"#PQHEK>1W=OI=M#/&<J\:;2.,=JS
M]#O+>QLH1(DBM=RDEPN55CT7/KBN@FGCMXR\CA5!QD]SZ4`%S:6]Y"8;J".:
M(]4D4,/UK!_X03P^K%H+-[;=U6WG>-3^`.*UK;44NKJ:!$D!A`WLRX`)[?6H
M9-=M8YI(@)9'C3?A$R7'^SZT`5;?P9X>MY/,&EP2RD8,DX,C'\6S5R[\/Z3?
M10Q76GV\L4`Q%&5^51].E2RZC##9K=2;PC+N"[?F(^E5EU^S9[<9DQ.,HVWC
M/I]:`(QX2T!9HY5TBT22,AE9(]I!'TK3NK2"]MI+:YC$D,@PZ'H145GJ$=]'
M(\2R+Y;E&#K@@BFWFJ6]DDK2,Q\I=SA%R5';-`%-/"/AZ-<+HUESU)B!/YFF
M#P9X<4872+=1G.%!`_(&MF*0R0H^UE+#.UNH^M24`%%%%`!1110`5E:\L\FE
M/%;QNV]E5Q&,L$SS@5JTAZ?C0!DVMB99K>1H3!:VP_<0L/F)_O-_A3+J&YN=
M=@7R&-O;J'#MPK.>Y]<#MZULXH[T`9&J0N=2L+EHI)H(2S%4&2'Q\IQ3M,MY
M;87=_>`)-<-YC+G/EH!P/KBM7M6+XHFDBT2XV-MW+M/'4&@#/M5N;_3KL1PR
M+/J4A8R,/D2+H#GOQGCWK3U.TE;2H-.M5?8[)$[C^&,=2?P&/QJ_9@+9PJ!A
M1&H`';@58Q@T`8\5L;R>T`M7M[2S)*I(,%G'`Q[8R??-,O'O?[6E9+6258H<
MP$CY`QZD^I["ML=,TG4T`9>A0306)-S&RS2L9'+_`'F8]<CM2:192+<75_<1
ME)YWPJ'JB#H*U>[4Z@#*UB">]\FQC1A#*V9Y1_"@[?4UG2VMTAN;Y+1MUNOD
M64(&2H[OBNE-'\7X4`95K!/8:&R10_OU0LJDY+,><GWS65]FO)EL;=K*46Y/
>G3^9C+R#^^>PS75=C2#DG/K0`HS@9ZTM':B@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
